Startup DreamersStartup Dreamers
  • Home
  • Startup
  • Money & Finance
  • Starting a Business
    • Branding
    • Business Ideas
    • Business Models
    • Business Plans
    • Fundraising
  • Growing a Business
  • More
    • Innovation
    • Leadership
Trending

No Phone, No Social Safety Net: Welcome to the ‘Offline Club’

February 2, 2026

Moltbot Is Taking Over Silicon Valley

February 1, 2026

ICE Asks Companies About ‘Ad Tech and Big Data’ Tools It Could Use in Investigations

January 30, 2026
Facebook Twitter Instagram
  • Newsletter
  • Submit Articles
  • Privacy
  • Advertise
  • Contact
Facebook Twitter Instagram
Startup DreamersStartup Dreamers
  • Home
  • Startup
  • Money & Finance
  • Starting a Business
    • Branding
    • Business Ideas
    • Business Models
    • Business Plans
    • Fundraising
  • Growing a Business
  • More
    • Innovation
    • Leadership
Subscribe for Alerts
Startup DreamersStartup Dreamers
Home » Nobel Prize Awarded For Seminal Work In Covid-19 Vaccine Development
Innovation

Nobel Prize Awarded For Seminal Work In Covid-19 Vaccine Development

adminBy adminOctober 3, 20234 ViewsNo Comments4 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email

Monday morning’s news that Drs. Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine has cast a spotlight on their seminal work leading to the development of the Covid-19 vaccines. The award, however, is not for the actual development of the vaccines. Rather, Karikó and Weissman have been recognized for basic research into our immunological response to mRNA and an atypical component of RNA called pseudouridine. Moreover, they have been recognized for work done over 15 years ago, long before the pandemic began.

“The vaccines have saved millions of lives,” the official Nobel Prize press release noted, “allowing societies to open and return to normal conditions.”

Although many people have discussed the rapid, some have said rushed, development of the Covid-19 vaccines, researchers have been exploring the idea of mRNA-based therapeutics for quite some time. Indeed, scientists have speculated about mRNA-based vaccines for roughly three decades. But, as is often the case in science, the path wasn’t straightforward.

Let’s start with a basic question. What is mRNA?

Produced in our cells using DNA as a template, messenger RNA, or mRNA, itself serves as a template to produce proteins, complex molecules that do most of the work in our cells. In the early 1980s, scientists developed a technique for generating mRNA in the laboratory. Quickly, they reasoned that if synthesized mRNA were introduced into a cell, then it should lead to the production of protein. In other words, we could “trick” cells into manufacturing proteins by adding to them a synthetic mRNA molecule.

The first obstacle proved to be getting the synthetic mRNA into cells. Lipid nanoparticles proved to be the answer to that problem. Composed of lipids very similar to the ones present in our own cells, lipid nanoparticles can fuse with our cells and deliver a cargo. If synthetic mRNA is encapsulated by a lipid nanoparticle, then it can be delivered.

But two other problems arose. First, when administered to animals, synthetic mRNA could trigger a detrimental inflammatory response. Second, protein production from synthetic mRNA in mammalian cells was weak. Not much protein was produced.

Here’s where Karikó and Weissman come in.

To investigate these problems, they synthesized mRNA in which they swapped out uridine, a typical building block of mRNA, for pseudouridine, a chemically similar building block.

The results were impressive. In a 2005 paper published in the journal Immunity, they showed that when synthesized RNA molecules containing pseudouridine instead of uridine were introduced into mammalian cells, the cells were less likely to express proinflammatory cytokines, signaling molecules that lead to potentially damaging inflammation. At the time of this article, the researchers noted that their findings could, “give future directions into the design of therapeutic RNAs.”

But what about the limited protein production problem? In a 2008 paper published in the journal Molecular Therapy, Karikó, Weissman and colleagues demonstrated that pseudouridine solved that problem, too. Again, they compared the activity of synthesized mRNA containing uridine to synthesized mRNA containing pseudouridine. In a series of experiments, conducted both in cells grown in the laboratory and in mice, they saw similar results. Pseudouridine-containing mRNA led to the production of significantly more protein.

Thus, the stage was set. By replacing uridine with pseudouridine in synthesized mRNA, the risk of an unwanted inflammatory response decreased, and the amount of protein produced increased. In other words, the incorporation of pseudouridine made the concept of an mRNA-based vaccine seem much more plausible.

When the world shut down in early 2020, researchers quickly turned this concept into a reality. Less than a year after the pandemic began, Moderna and Pfizer-BioNTech began testing mRNA-based vaccines. The rapid, but not rushed, development of these vaccines certainly changed the course of the pandemic. As the Nobel Prize press release notes, these vaccines probably saved millions of lives. And for their important contributions to the process, Drs. Katalin Karikó and Drew Weissman will now go rightfully down in history as Nobel Laureates.

Read the full article here

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Articles

Today’s Wordle #1686 Hints And Answer For Friday, January 30

Innovation January 30, 2026

Today’s Wordle #1685 Hints And Answer For Thursday, January 29

Innovation January 29, 2026

Today’s Wordle #1684 Hints And Answer For Wednesday, January 28

Innovation January 28, 2026

U.S. Revamps Wildfire Response Into Modern Central Organization

Innovation January 27, 2026

Studies Are Increasingly Finding High Blood Sugar May Be Associated With Dementia

Innovation January 26, 2026

Google’s Last Minute Offer For Pixel Customers

Innovation January 25, 2026
Add A Comment

Leave A Reply Cancel Reply

Editors Picks

No Phone, No Social Safety Net: Welcome to the ‘Offline Club’

February 2, 2026

Moltbot Is Taking Over Silicon Valley

February 1, 2026

ICE Asks Companies About ‘Ad Tech and Big Data’ Tools It Could Use in Investigations

January 30, 2026

Today’s Wordle #1686 Hints And Answer For Friday, January 30

January 30, 2026

Meta Seeks to Bar Mentions of Mental Health—and Zuckerberg’s Harvard Past—From Child Safety Trial

January 29, 2026

Latest Posts

The Math on AI Agents Doesn’t Add Up

January 28, 2026

Today’s Wordle #1684 Hints And Answer For Wednesday, January 28

January 28, 2026

How Claude Code Is Reshaping Software—and Anthropic

January 27, 2026

U.S. Revamps Wildfire Response Into Modern Central Organization

January 27, 2026

Studies Are Increasingly Finding High Blood Sugar May Be Associated With Dementia

January 26, 2026
Advertisement
Demo

Startup Dreamers is your one-stop website for the latest news and updates about how to start a business, follow us now to get the news that matters to you.

Facebook Twitter Instagram Pinterest YouTube
Sections
  • Growing a Business
  • Innovation
  • Leadership
  • Money & Finance
  • Starting a Business
Trending Topics
  • Branding
  • Business Ideas
  • Business Models
  • Business Plans
  • Fundraising

Subscribe to Updates

Get the latest business and startup news and updates directly to your inbox.

© 2026 Startup Dreamers. All Rights Reserved.
  • Privacy Policy
  • Terms of use
  • Press Release
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

GET $5000 NO CREDIT